Your session is about to expire
← Back to Search
NMDA Receptor Antagonist
Ketamine Imaging for Mood Disorders
N/A
Recruiting
Led By Irina Esterlis, PhD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Subjects undergoing ketamine treatment must meet DSM-5 diagnostic criteria for Major Depressive Disorder and for a current depressive episode as assessed by structured interview for DSM-5 diagnosis (SCID) and be undergoing ketamine treatment
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion date, an average of 5 years.
Awards & highlights
Study Summary
This trial is designed to study the effects of ketamine on synaptic density in people with depression or PTSD.
Who is the study for?
This trial is for adults aged 18-70 with Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), who understand the study's research nature. Healthy individuals without any DSM-5 diagnosis can also participate. Exclusions include neurological issues, low IQ, substance abuse, certain medical conditions, and contraindications to MRI or PET scans like claustrophobia.Check my eligibility
What is being tested?
The study investigates how ketamine affects synaptic density in people with MDD and PTSD using imaging techniques like MRI and PET scans. Participants will undergo cognitive tests and a stress test on scan days to see if ketamine can reverse changes associated with these disorders.See study design
What are the potential side effects?
While not explicitly listed in the provided information, common side effects of ketamine may include confusion, hallucinations, changes in blood pressure, dizziness, nausea, and blurred vision during the short-term post-administration period.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am diagnosed with Major Depressive Disorder and currently receiving ketamine treatment.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion date, an average of 5 years.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion date, an average of 5 years.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Evidence of synaptic changes in psychiatric disorders confirmed by PET data.
Evidence of synaptic density at time of its greatest anti-depressant response in psychiatric disorders confirmed with PET data.
Trial Design
3Treatment groups
Active Control
Group I: PET scans for subjects undergoing ketamine treatmentActive Control1 Intervention
For subjects currently undergoing treatment with ketamine. Subjects will participate in 1-3 PET scans (up to 4 if cancelations occur) on the High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or the HR+ will be used to image subjects. Vital signs (blood pressure and pulse) will be obtained before and after radiotracer administration. Venous catheter(s) will be used for IV administration of the radiotracer and for venous blood sampling. An arterial catheter will be inserted by an experienced physician before the PET scan. Baseline scan will occur prior to initiation of ketamine treatment. Subsequent scans will occur after several treatments with ketamine and after completion of treatment.
Bipolar subjects will not participate in any ketamine arms.
Group II: PET scans and ketamine administrationActive Control1 Intervention
Subjects will participate in 2-3 PET scans (up to 4 if cancelations occur) on the High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or the HR+ will be used to image subjects. Vital signs (blood pressure and pulse) will be obtained before and after radiotracer administration. Venous catheter(s) will be used for IV administration of the radiotracer and for venous blood sampling. An arterial catheter will be inserted by an experienced physician before the PET scan. After a baseline scan, subjects will be administered a low dose of ketamine for the second scan.
Bipolar subjects will not participate in any ketamine arms.
Group III: Single PET scanActive Control1 Intervention
Subjects will participate in 1 PET scan (up to 2 if cancelations occur) on the High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or the HR+ will be used to image subjects. Vital signs (blood pressure and pulse) will be obtained before and after radiotracer administration. Venous catheter(s) will be used for IV administration of the radiotracer and for venous blood sampling. An arterial catheter will be inserted by an experienced physician before the PET scan.
Find a Location
Who is running the clinical trial?
VA Office of Research and DevelopmentFED
1,621 Previous Clinical Trials
3,323,371 Total Patients Enrolled
78 Trials studying Depression
20,733 Patients Enrolled for Depression
Yale UniversityLead Sponsor
1,865 Previous Clinical Trials
2,742,615 Total Patients Enrolled
64 Trials studying Depression
20,646 Patients Enrolled for Depression
Irina Esterlis, PhDPrincipal Investigator - Yale School of Medicine
Yale University
3 Previous Clinical Trials
349 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am between 18 and 70 years old.You understand that this study is solely for research purposes and not for medical treatment.You do not have any current or past mental health conditions as defined by the DSM-5.I have been diagnosed with bipolar disorder according to DSM-5.I have never had a major brain condition, injury, or long-term memory loss.I cannot have a PET scan due to past cancer or issues with my veins.I have been diagnosed with major depression or PTSD with psychotic features.I weigh less than 110 lbs.I am currently diagnosed with PTSD.I am between 18 and 70 years old, speak English, and have no mental health diagnoses except as specified.I am diagnosed with Major Depressive Disorder and currently receiving ketamine treatment.You do not have any other mental health conditions, except for the ones listed below.I am currently diagnosed with PTSD.I have a bleeding disorder or am currently on blood thinners.
Research Study Groups:
This trial has the following groups:- Group 1: PET scans for subjects undergoing ketamine treatment
- Group 2: PET scans and ketamine administration
- Group 3: Single PET scan
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Depression Patient Testimony for trial: Trial Name: NCT02734602 — N/A
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger